Photodynamic therapy with verteporfin: Observations on the introduction of a new treatment into clinical practice

Archives of Ophthalmology

Volumn 123, Issue 1, 2005, Pages 58-63

  Schein, Oliver D ^a   Bressler, Neil M ^a   Price, Patrick ^b  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b Blue Cross and Blue Shield of Kansas   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BENZOPORPHYRIN DERIVATIVE;

CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; FLUORESCENCE ANGIOGRAPHY; FOOD AND DRUG ADMINISTRATION; HEALTH CARE COST; HEALTH CARE DELIVERY; HEALTH MAINTENANCE ORGANIZATION; HUMAN; MEDICARE; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; REVIEW; SUBRETINAL NEOVASCULARIZATION; VISUAL IMPAIRMENT;

CHOROIDAL NEOVASCULARIZATION; COST-BENEFIT ANALYSIS; DELIVERY OF HEALTH CARE; DRUG APPROVAL; DRUG UTILIZATION REVIEW; FEE-FOR-SERVICE PLANS; FLUORESCEIN ANGIOGRAPHY; GUIDELINE ADHERENCE; HEALTH MAINTENANCE ORGANIZATIONS; HEALTH SERVICES RESEARCH; HUMANS; MACULAR DEGENERATION; MEDICARE; PHOTOCHEMOTHERAPY; PHOTOGRAPHY; PHOTOSENSITIZING AGENTS; PORPHYRINS; PRACTICE GUIDELINES; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 12144274842     PISSN: 00039950     EISSN: None     Source Type: Journal    
DOI: 10.1001/archopht.123.1.58     Document Type: Review

References (20)

1. Age-Related Eye Disease Study Research Group. Potential public health impact of Age-Related Eye Disease Study results: AREDS report No. 11. Arch Ophthalmol. 2003;121:1621-1624.
2. Macular Photocoagulation Study Group. Persistent and recurrent neovascularization after krypton laser photocoagulation for neovascular lesions of ocular histoplasmosis. Arch Ophthalmol. 1989;107:344-352.
3. Macular Photocoagulation Study Group. Laser photocoagulation of subfoveal neovascular lesions in age-related macular degeneration: results of a randomized clinical trial. Arch Ophthalmol. 1991;109:1220-1231.
4. Macular Photocoagulation Study Group. Laser photocoagulation of subfoveal recurrent neovascular lesions in age-related macular degeneration: results of a randomized clinical trial. Arch Ophthalmol. 1991;109:1232-1241.
5. Treatment of Age-Related Macular Degeneration With Photodynamic Therapy (TAP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials: TAP report. Arch Ophthalmol. 1999;117:1329-1345.
6. Treatment of Age-Related Macular Degeneration With Photodynamic Therapy (TAP) Study Group, Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: two-year results of 2 randomized clinical trials: TAP report 2. Arch Ophthalmol. 2001;119:198-207.
7. Verteporfin in Photodynamic Therapy (VIP) Study Group. Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two-year results of a randomized clinical trial including lesions with occult but no classic choroidal neovascularization: VIP report 2. Am J Ophthalmol. 2001; 131:541-560.
8. US Department of Health and Human Services. National coverage policy for photodynamic therapy. In: Medicare Coverage Issues Manual. Washington, DC: US Dept of Health and Human Services; 2001. HCFA publication 6, section 35-100.
9. Treatment of Age-Related Macular Degeneration With Photodynamic Therapy (TAP) Study Group. Verteporfin therapy of subfoveal choroidal neovascularization in patients with age-related macular degeneration: additional information regarding baseline lesion composition's impact on vision outcomes: TAP report No. 3. Arch Ophthalmol. 2002;120:1443-1454.
10. Treatment of Age-Related Macular Degeneration With Photodynamic Therapy (TAP) Study Group and Verteporfin in Photodynamic Therapy (VIP) Study Group. Effect of baseline lesion size, visual acuity, and lesion composition on visual acuity change from baseline with and without verteporfin therapy in choroidal neovascularization secondary to age-related macular degeneration: TAP and VIP report No. 1. Am J Ophthalmol. 2003;136:407-418.
11. Centers for Medicare & Medicaid Services. Ocular photodynamic therapy with verteporfin for macular degeneration (CAG-00066R3). Available at: http://www.cms.hhs.gov/medlearn/matters/mmarticles/2004/MM3191.pdf. Accessed January 31, 2004.
12. Macular Photocoagulation Study Group. Subfoveal neovascular lesions in age-related macular degeneration: guidelines for evaluation and treatment in the Macular Photocoagulation Study. Arch Ophthalmol. 1991;109:1242-1257.
13. Verteporfin Roundtable 2000 and 2001 Participants, Treatment of Age-Related Macular Degeneration With Photodynamic Therapy (TAP) Study Group Principal Investigators, Verteporfin in Photodynamic Therapy (VIP) Study Group Principal Investigators. Guidelines for using verteporfin (Visudyne®) in photodynamic therapy to treat choroidal neovascularization due to age-related macular degeneration and other causes. Retina. 2002;22:6-18.
14. American Academy of Ophthalmology. Preferred practice pattern: age-related macular degeneration. Available at: http://www.aao.org/aao/ education/library/ppp/loader.cfm?url=/commonspot/security/getfile. cfm&PageID=31760. Accessed January 31, 2004.
15. Cabana MD, Rand CS, Powe NR, et al. Why don't physicians follow clinical practice guidelines? a framework for improvement. JAMA. 1999;282:1458-1465.
16. Holz FG, Jorzik J, Schutt F, Flach U, Unnebrink K. Agreement among ophthalmologists in evaluating fluorescein angiograms in patients with neovascular age-related macular degeneration for photodynamic therapy eligibility (FLAP-study). Ophthalmology. 2003;110:400-405.
17. Bressler NM. Photodynamic therapy: current treatment guidelines for choroidal neovascularization (CNV). In: The AAO Program Book for 2002 Annual Meeting. San Francisco, Calif: American Academy of Ophthalmology; 2002. Course 164.
18. Treatment of Age-Related Macular Degeneration With Photodynamic Therapy (TAP) and Verteporfin in Photodynamic Therapy (VIP) Study Groups. Photodynamic therapy of subfoveal choroidal neovascularization with verteporfin: fluorescein angiographic guidelines for evaluation and treatment: TAP and VIP report No. 2. Arch Ophthalmol. 2003;121:1253-1268.
19. Foote SB. Focus on locus: evolution of Medicare's local coverage policy. Health Aff (Millwood). 2003;22:137-146.
20. Foote SB. Why Medicare cannot promulgate a national coverage rule: a case of regula mortis. J Health Polit Policy Law. 2002;27:707-714.